Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
wIPV-wIPV-bOPV
- Development stage
- Phase 4
- Lead developer
- Parent
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Oral
01
Overview
wIPV-wIPV-bOPV appears to be a polio vaccination schedule that combines two doses of inactivated poliovirus vaccine (IPV) followed by a dose of bivalent oral poliovirus vaccine (bOPV). This combination approach aims to provide both humoral immunity through IPV and mucosal immunity through OPV. IPV contains killed poliovirus that cannot cause disease but stimulates antibody production, while bOPV contains weakened live virus strains that can provide intestinal immunity but carries a small risk of vaccine-derived poliovirus.
02
Targets
CD4+ T-cell receptor recognizing poliovirus capsid-derived peptidesPV-TCR (Poliovirus capsid-specific CD8+ T-cell receptor)PRR (Pattern recognition receptors)PV-D-BCR (Naïve B-cell receptor specific for poliovirus D-antigen)
Beyond the preview
Go deeper on wIPV-wIPV-bOPV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on wIPV-wIPV-bOPV.